1. Home
  2. HIMX vs SNDX Comparison

HIMX vs SNDX Comparison

Compare HIMX & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HIMX
  • SNDX
  • Stock Information
  • Founded
  • HIMX 2001
  • SNDX 2005
  • Country
  • HIMX Taiwan
  • SNDX United States
  • Employees
  • HIMX N/A
  • SNDX N/A
  • Industry
  • HIMX Semiconductors
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HIMX Technology
  • SNDX Health Care
  • Exchange
  • HIMX Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • HIMX 1.6B
  • SNDX 1.3B
  • IPO Year
  • HIMX 2006
  • SNDX 2016
  • Fundamental
  • Price
  • HIMX $8.75
  • SNDX $15.31
  • Analyst Decision
  • HIMX Buy
  • SNDX Strong Buy
  • Analyst Count
  • HIMX 1
  • SNDX 12
  • Target Price
  • HIMX $15.00
  • SNDX $37.42
  • AVG Volume (30 Days)
  • HIMX 951.4K
  • SNDX 3.9M
  • Earning Date
  • HIMX 11-06-2025
  • SNDX 11-03-2025
  • Dividend Yield
  • HIMX 4.25%
  • SNDX N/A
  • EPS Growth
  • HIMX N/A
  • SNDX N/A
  • EPS
  • HIMX 0.42
  • SNDX N/A
  • Revenue
  • HIMX $889,561,000.00
  • SNDX $111,304,000.00
  • Revenue This Year
  • HIMX N/A
  • SNDX $636.61
  • Revenue Next Year
  • HIMX $16.64
  • SNDX $114.95
  • P/E Ratio
  • HIMX $21.91
  • SNDX N/A
  • Revenue Growth
  • HIMX N/A
  • SNDX 595.65
  • 52 Week Low
  • HIMX $5.12
  • SNDX $8.58
  • 52 Week High
  • HIMX $13.91
  • SNDX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • HIMX 44.49
  • SNDX 55.86
  • Support Level
  • HIMX $9.36
  • SNDX $13.00
  • Resistance Level
  • HIMX $9.70
  • SNDX $15.79
  • Average True Range (ATR)
  • HIMX 0.30
  • SNDX 1.18
  • MACD
  • HIMX -0.05
  • SNDX -0.01
  • Stochastic Oscillator
  • HIMX 11.21
  • SNDX 76.02

About HIMX Himax Technologies Inc.

Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: